The DOI matches its Crossref record.
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study
Abstract
Background: Imatinib mesylate is a small molecule inhibitor of certain tyrosine kinases, most notably the chimeric bcr‐abl fusion protein found in CML. It also inhibits KIT and PDGF receptor tyrosine kinases in vitro. Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic small round cell, and synovial sarcomas often overexpress KIT or the PDGF receptor. A phase II study of imatinib in children and young adults with select solid tumors was performed. Procedure: Patients less than 30 years of age with refractory or recurrent Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic small round cell, synovial sarcomas or GIST were eligible. Imatinib was administered daily for 28 day courses at a dose of 440 mg/m 2/day. Responses were assessed according to Response Evaluation Criteria in Solid Tumor (RECIST). Results: Seventy eligible patients, 48 male and 22 female, were enrolled and 59 were evaluable for response. Only one partial response was seen among 24 patients with Ewing sarcoma. There were no other objective responses. Hemorrhagic pleural effusions occurred in seven patients with pulmonary lesions, four of whom had progressive disease at the time of the hemorrhage. Intratumoral bleeding was reported in three additional patients. Conclusion: Imatinib as a single agent at a dose of 440 mg/m 2/day demonstrated little or no activity as a single agent in children with relapsed or refractory Ewing sarcoma, osteosarcoma, neuroblastoma, or desmoplastic small round cell tumors. Pediatr Blood Cancer 2008;50:254–258. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Balamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Gastrointestinal Stromal Tumors
von Mehren, M., & Joensuu, H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9705 · Cited by 306
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Metadata
- Authors
- Bond, M., Bernstein, M. L., Pappo, A., Schultz, K. R., Krailo, M., Blaney, S. M., & Adamson, P. C.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2007-01-29
- Volume
- 50
- Issue
- 2
- Pages
- 254-258
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2077014658
- Cited by
- 211
- References
- 0
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. https://app.cochat.ai/papers/10.1002/pbc.21132
- The paper
- Bond, M., Bernstein, M. L., Pappo, A., Schultz, K. R., Krailo, M., Blaney, S. M., & Adamson, P. C. (2008). A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.21132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.